drugset / Trial / NCT04434040
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Phase 2
Recruiting
40 enrolled
Dana-Farber Cancer Institute
Genentech, Inc. · collabStand Up To Cancer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacituzumab govitecan * Atezolizumab
Timeline
- Start
- 2020-07-02
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | Intravenous |